It measures the expression levels of multiple markers associated with aggressive prostate cancer and provides additional information about a patient’s risk of disease progression after surgery.
Read More
Including p63 in Biocare’s lung, prostate, and breast panels empowers its Multiplex IHC platform to aid pathologists in making critical decisions.
Read More
Washington University research demonstrates the incidence of biopsy sample misidentification, and cost-effectiveness of DNA provenance testing as part of the diagnostic testing cycle for cancer.
Read More
A genetic test for the T nucleotide of this genetic variant can identify bladder cancer patients who could benefit from this treatment.
Read More
Researchers might some day be able to test prostate cancer patients for the presence of a specific molecule, to help identify those who are most at risk for aggressive cancer.
Read More